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Sir,	26	
	27	
We	write	in	response	to	an	article	regarding	the	antibiotic	batumin	by	Klochko	et	al.	28	
that	appeared	earlier	this	year	in	the	journal	[1].	The	stated	aim	of	this	study	was	“to	29	
identify	 possible	 molecular	 targets	 for	 batumin	 as	 well	 as	 mechanisms	 of	 its	30	
antistaphylococcal	activity”.	Apparently	on	the	basis	that	batumin	and	the	clinically	31	
deployed	antibacterial	drug	mupirocin	share	a	9-hydroxynonanoic	acid	moiety,	and	32	
that	 the	 biosynthesis	 of	 both	 antibiotics	 is	 directed	 by	 operons	 that	 exhibit	 some	33	
degree	of	sequence	similarity,	the	authors	formulated	the	hypothesis	that	batumin	34	
shares	the	same	molecular	target	as	mupirocin:	the	isoleucyl-tRNA	synthetase	(IleRS)	35	
enzyme	 that	 plays	 an	 essential	 role	 in	 protein	 synthesis.	With	 a	 view	 to	 providing	36	
support	for	this	hypothesis,	Klochko	et	al.	undertook	two	in	silico	investigations.	The	37	
first	of	these	involved	molecular	docking	of	batumin	into	X-ray	crystal	structures	of	38	
IleRS,	 the	 results	 of	 which	 implied	 that	 batumin	 and	 mupirocin	 might	 bind	 with	39	
similar	affinity	to	this	enzyme.	The	second	entailed	analysis	of	the	genome	sequence	40	
of	 a	 batumin	 producer	 organism	 (P.	 batumici),	 which	 led	 to	 the	 identification	 of	41	
three	genes	encoding	paralogues	of	 leucyl-tRNA	synthetase	(LeuRS),	and	prompted	42	
the	authors	to	suggest	that	batumin	might	also/	predominantly	target	LeuRS.		43	
	44	
Whilst	 in	silico	analyses	such	as	 these	may	have	a	place	 in	generating	or	refining	a	45	
hypothesis	as	to	the	mode	of	action	(MOA)	of	batumin,	the	results	they	provide	are	46	
predictions	at	best,	and	do	not	constitute	evidence	 to	support	 the	hypothesis	 that	47	
batumin	 acts	 by	 inhibiting	 aminoacyl-tRNA	 synthetase	 (aaRS)	 enzymes.	 In	48	
consequence,	and	lacking	a	direct	experiment	to	test	their	hypothesis,	the	study	by	49	
Klochko	et	al.	did	not	progress	beyond	pure	speculation.	Though	the	authors	made	50	
mention	 of	 the	 fact	 that	 their	 ideas	 would	 ultimately	 require	 experimental	51	
corroboration,	this	did	not	prevent	them	from	presenting	firm	conclusions	regarding	52	
the	MOA	of	batumin	that	went	well	beyond	what	their	results	could	justify	(e.g.	“It	53	
was	 found	 that	 batumin	 acted	 very	 similarly	 to	mupirocin	 by	 inhibiting	 aminoacyl	54	
tRNA	 synthetases.”).	 Here	 we	 present	 experimental	 evidence	 to	 show	 that	 their	55	
conclusions	regarding	the	MOA	of	batumin	are	in	fact	wrong.	56	
	57	
Antibiotics	that	mediate	their	antibacterial	effect	through	inhibition	of	aaRS	enzymes	58	
will	 act	 to	 rapidly	 deplete	 the	 bacterial	 cell	 of	 charged	 tRNA	 species,	 an	 early	59	
consequence	 of	 which	 will	 be	 inhibition	 of	 protein	 synthesis.	 For	 example,	 when	60	
mupirocin	at	4XMIC	is	added	to	logarithmic	phase	cultures	of	Staphylococcus	aureus	61	
strain	SH1000,	a	dramatic	 (~65%)	 reduction	 in	protein	synthesis	 is	observed	within	62	
10	 minutes	 relative	 to	 an	 untreated	 control,	 as	 determined	 [2]	 by	 measuring	63	
incorporation	 of	 the	 radiolabeled	 amino	 acid	 L-[3,4-
3
H(N)]-glutamine	 into	64	
polypeptides	 (Figure	 1).	 By	 contrast,	 in	 an	 otherwise	 identical	 experiment	 using	65	
batumin	 (Enzo	 Life	 Sciences,	 Exeter,	 UK)	 at	 4XMIC	 in	 place	 of	 mupirocin,	 no	66	
inhibition	of	protein	synthesis	was	observed	(Figure	1).	It	is	therefore	apparent	that	67	
the	antibacterial	action	of	batumin	is	distinct	from	that	of	mupirocin,	and	does	not	68	
involve	inhibition	of	one	or	more	aaRS	enzymes.		69	
	70	
A	prior	 hypothesis	 regarding	 the	MOA	of	 batumin	 considered	 that	 this	 compound	71	
exerts	its	antibacterial	effect	through	direct	inhibition	of	fatty	acid	biosynthesis	[3].	72	
This	proposal	stemmed	from	the	observation	that	an	isoform	(BatG)	of	the	fatty	acid	73	
synthesis	enzyme,	FabI,	is	encoded	within	the	batumin	biosynthesis	cluster	in	some	74	
producer	strains,	and	that	heterologous	expression	of	batG	in	Escherichia	coli	and	S.	75	
aureus	confers	a	substantial	 reduction	 in	batumin	susceptibility	 [3].	With	a	view	to	76	
reconciling	their	speculations	with	these	observations,	Klochko	et	al.	proposed	that	77	
both	 batumin	 and	 mupirocin	 mediate	 their	 antibacterial	 effect	 by	 indirectly	78	
impairing	 fatty	 acid	 synthesis	 as	 a	 secondary	 consequence	 of	 inhibiting	 aaRS	79	
enzymes	 and	 inducing	 the	 stringent	 response.	We	 examined	 the	 effect	 of	 4X	MIC	80	
batumin	on	fatty	acid	synthesis	 in	S.	aureus	SH1000	by	measuring	 incorporation	of	81	
the	 radiolabeled	precursor,	 [1,2-
14
C]-acetic	 acid.	Batumin	and	a	 known	 inhibitor	of	82	
this	 pathway,	 triclosan,	 both	 caused	 a	 dramatic	 reduction	 (>60%)	 in	 fatty	 acid	83	
synthesis	 relative	 to	 the	 untreated	 control	 in	 10	minutes	 (Figure	 1).	 That	 batumin	84	
achieved	such	rapid	and	substantial	inhibition	of	fatty	acid	synthesis,	and	before	any	85	
detectable	 impact	 on	 the	 synthesis	 of	 other	 cellular	 macromolecules	 (protein),	86	
corroborates	 the	 original	 hypothesis	 that	 batumin	 directly	 inhibits	 fatty	 acid	87	
synthesis.	 The	 proposal	 that	 aaRS	 inhibitors	 ultimately	mediate	 their	 antibacterial	88	
effects	 through	 indirect	 inhibition	 of	 fatty	 acid	 synthesis	 is	 not	 supported	 by	 the	89	
observation	that	mupirocin,	though	demonstrating	considerable	inhibition	of	protein	90	
synthesis,	exerted	no	inhibitory	effect	on	fatty	acid	synthesis	(Figure	1).	91	
	92	
Thus,	 whilst	 further	 experimental	 studies	 will	 be	 required	 to	 more	 precisely	93	
delineate	the	MOA	of	batumin,	the	available	evidence	discounts	inhibition	of	one	or	94	
more	 aaRS	 enzymes,	 and	 implies	 that	 batumin	 mediates	 its	 antibacterial	 effect	95	
directly	through	inhibition	of	fatty	acid	biosynthesis.	96	
	97	
	98	
	99	
Figure	1.	Effect	of	batumin	and	control	agents	at	4XMIC	on	protein	and	fatty	acid	100	
synthesis	 in	 S.	 aureus	 SH1000,	 as	 measured	 by	 incorporation	 of	 radiolabeled	101	
precursors	over	a	10	minute	period.	Incorporation	is	shown	as	a	percentage	of	that	102	
in	 the	 untreated	 control.	 Datum	 points	 represent	 the	 means	 of	 at	 least	 three	103	
experimental	determinations,	and	error	bars	show	standard	deviations.	104	
	105	
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